» Articles » PMID: 38192406

Cell-type Specific Role of Autophagy in the Liver and Its Implications in Non-alcoholic Fatty Liver Disease

Overview
Journal World J Hepatol
Specialty Gastroenterology
Date 2024 Jan 9
PMID 38192406
Authors
Affiliations
Soon will be listed here.
Abstract

Autophagy, a cellular degradative process, has emerged as a key regulator of cellular energy production and stress mitigation. Dysregulated autophagy is a common phenomenon observed in several human diseases, and its restoration offers curative advantage. Non-alcoholic fatty liver disease (NAFLD), more recently renamed metabolic dysfunction-associated steatotic liver disease, is a major metabolic liver disease affecting almost 30% of the world population. Unfortunately, NAFLD has no pharmacological therapies available to date. Autophagy regulates several hepatic processes including lipid metabolism, inflammation, cellular integrity and cellular plasticity in both parenchymal (hepatocytes) and non-parenchymal cells (Kupffer cells, hepatic stellate cells and sinusoidal endothelial cells) with a profound impact on NAFLD progression. Understanding cell type-specific autophagy in the liver is essential in order to develop targeted treatments for liver diseases such as NAFLD. Modulating autophagy in specific cell types can have varying effects on liver function and pathology, making it a promising area of research for liver-related disorders. This review aims to summarize our present understanding of cell-type specific effects of autophagy and their implications in developing autophagy centric therapies for NAFLD.

Citing Articles

Thyroid Hormone-Mediated Selective Autophagy and Its Implications in Countering Metabolic Dysfunction-Associated Steatotic Liver Disease.

Sinha R Endocrinol Metab (Seoul). 2024; 39(5):686-692.

PMID: 39397515 PMC: 11525703. DOI: 10.3803/EnM.2024.2068.


Autophagy and hepatic lipid metabolism: mechanistic insight and therapeutic potential for MASLD.

Raza S, Rajak S, Yen P, Sinha R NPJ Metab Health Dis. 2024; 2(1):19.

PMID: 39100919 PMC: 11296953. DOI: 10.1038/s44324-024-00022-5.


Autophagy and inflammation an intricate affair in the management of obesity and metabolic disorders: evidence for novel pharmacological strategies?.

Friuli M, Sepe C, Panza E, Travelli C, Paterniti I, Romano A Front Pharmacol. 2024; 15:1407336.

PMID: 38895630 PMC: 11184060. DOI: 10.3389/fphar.2024.1407336.


Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications.

Guo Z, Wu Q, Xie P, Wang J, Lv W Front Immunol. 2024; 15:1336493.

PMID: 38352880 PMC: 10861763. DOI: 10.3389/fimmu.2024.1336493.

References
1.
Chakravarthy M, Neuschwander-Tetri B . The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab. 2020; 3(4):e00112. PMC: 7576253. DOI: 10.1002/edm2.112. View

2.
Raza S, Tewari A, Rajak S, Sinha R . Vitamins and non-alcoholic fatty liver disease: A Molecular Insight. Liver Res. 2021; 5(2):62-71. PMC: 7611112. DOI: 10.1016/j.livres.2021.03.004. View

3.
Duwaerts C, Maiers J . ER Disposal Pathways in Chronic Liver Disease: Protective, Pathogenic, and Potential Therapeutic Targets. Front Mol Biosci. 2022; 8:804097. PMC: 8841999. DOI: 10.3389/fmolb.2021.804097. View

4.
Sheldon R, Meers G, Morris E, Linden M, Cunningham R, Ibdah J . eNOS deletion impairs mitochondrial quality control and exacerbates Western diet-induced NASH. Am J Physiol Endocrinol Metab. 2019; 317(4):E605-E616. PMC: 6842915. DOI: 10.1152/ajpendo.00096.2019. View

5.
Fukuo Y, Yamashina S, Sonoue H, Arakawa A, Nakadera E, Aoyama T . Abnormality of autophagic function and cathepsin expression in the liver from patients with non-alcoholic fatty liver disease. Hepatol Res. 2013; 44(9):1026-36. DOI: 10.1111/hepr.12282. View